JP2021518377A5 - - Google Patents

Info

Publication number
JP2021518377A5
JP2021518377A5 JP2020550099A JP2020550099A JP2021518377A5 JP 2021518377 A5 JP2021518377 A5 JP 2021518377A5 JP 2020550099 A JP2020550099 A JP 2020550099A JP 2020550099 A JP2020550099 A JP 2020550099A JP 2021518377 A5 JP2021518377 A5 JP 2021518377A5
Authority
JP
Japan
Prior art keywords
triazole
dihydro
aminomethyl
fluoropropane
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020550099A
Other languages
English (en)
Japanese (ja)
Other versions
JP7322052B2 (ja
JP2021518377A (ja
Filing date
Publication date
Priority claimed from KR1020180032554A external-priority patent/KR20190110740A/ko
Application filed filed Critical
Publication of JP2021518377A publication Critical patent/JP2021518377A/ja
Publication of JP2021518377A5 publication Critical patent/JP2021518377A5/ja
Priority to JP2023121661A priority Critical patent/JP2023134824A/ja
Application granted granted Critical
Publication of JP7322052B2 publication Critical patent/JP7322052B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550099A 2018-03-21 2019-03-20 新規アリールもしくはヘテロアリールトリアゾロン誘導体もしくはそれらの塩、またはそれを含む医薬組成物 Active JP7322052B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023121661A JP2023134824A (ja) 2018-03-21 2023-07-26 新規アリールもしくはヘテロアリールトリアゾロン誘導体もしくはそれらの塩、またはそれを含む医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180032554A KR20190110740A (ko) 2018-03-21 2018-03-21 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR10-2018-0032554 2018-03-21
PCT/IB2019/052276 WO2019180644A1 (en) 2018-03-21 2019-03-20 Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023121661A Division JP2023134824A (ja) 2018-03-21 2023-07-26 新規アリールもしくはヘテロアリールトリアゾロン誘導体もしくはそれらの塩、またはそれを含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2021518377A JP2021518377A (ja) 2021-08-02
JP2021518377A5 true JP2021518377A5 (enExample) 2022-03-11
JP7322052B2 JP7322052B2 (ja) 2023-08-07

Family

ID=67986856

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020550099A Active JP7322052B2 (ja) 2018-03-21 2019-03-20 新規アリールもしくはヘテロアリールトリアゾロン誘導体もしくはそれらの塩、またはそれを含む医薬組成物
JP2023121661A Pending JP2023134824A (ja) 2018-03-21 2023-07-26 新規アリールもしくはヘテロアリールトリアゾロン誘導体もしくはそれらの塩、またはそれを含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023121661A Pending JP2023134824A (ja) 2018-03-21 2023-07-26 新規アリールもしくはヘテロアリールトリアゾロン誘導体もしくはそれらの塩、またはそれを含む医薬組成物

Country Status (10)

Country Link
US (3) US10562865B2 (enExample)
EP (1) EP3768663A4 (enExample)
JP (2) JP7322052B2 (enExample)
KR (2) KR20190110740A (enExample)
CN (1) CN111886227B (enExample)
AR (1) AR115006A1 (enExample)
AU (1) AU2019237342B2 (enExample)
CA (1) CA3093051A1 (enExample)
TW (1) TWI825079B (enExample)
WO (1) WO2019180644A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20200004036A (ko) * 2018-07-03 2020-01-13 주식회사유한양행 (e)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 유도체의 제조방법
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
AU2020206477B2 (en) 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof
KR20220145981A (ko) * 2021-04-22 2022-11-01 주식회사유한양행 트리아졸론, 테트라졸론, 및 이미다졸론, 또는 그의 염, 및 그를 포함하는 제약 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725148A1 (de) 1977-06-03 1978-12-14 Hoechst Ag 1-aryl-4-alkyl-1,2,4-triazol-5-one und verfahren zu ihrer herstellung
WO2005014530A2 (en) 2003-08-08 2005-02-17 La Jolla Pharmaceutical Co. Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment of diseases
KR100572996B1 (ko) 2003-08-12 2006-04-25 한국화학연구원 불소화 비닐 에테르 측쇄기를 갖는 아졸계 살균제 화합물및 그의 제조방법
AU2005216955A1 (en) * 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US20070293548A1 (en) 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
EP2139333A4 (en) 2007-03-28 2010-11-10 Merck Sharp & Dohme SUBSTITUTED PYRID- [3,2-E] - [1,2,4] -TRIAZOL- [4,3-C] -PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
WO2008119662A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
GB0722075D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
CN101917845A (zh) 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
EP2822931B1 (en) * 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2013255103B2 (en) 2012-05-02 2016-09-29 Syntara Limited Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
BR112015026631A2 (pt) * 2013-04-25 2017-07-25 Yuhan Corp compostos ou sais farmaceuticamente aceitáveis dos mesmos e respectivos usos, composição farmacêutica e método para prevenir ou tratar diabetes melito em mamífero
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
TW201722958A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
EA201891674A1 (ru) 2016-02-12 2019-01-31 Фармаксис Лтд. Ингибиторы лизилоксидаз, представляющие собой индольные и азаиндольные производные галогеналлиламина, и их применения
EP3452469A1 (en) 2016-05-03 2019-03-13 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
US20210212968A1 (en) 2016-10-19 2021-07-15 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
EP3589619A4 (en) 2017-03-02 2020-12-16 Pharmaxis Ltd. LYSYL OXIDASE INHIBITORS, HALOGENOALLYLAMINE PYRAZOLE DERIVATIVES AND THEIR USES
US20200087248A1 (en) 2017-04-28 2020-03-19 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fluoroallylamine Derivative And Use Thereof
AU2018287777B2 (en) 2017-06-20 2020-05-21 Shandong Danhong Pharmaceutical Co., Ltd. SSAO inhibitor
CN109810041B (zh) 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988109B (zh) 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN110938059A (zh) 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
CA3114166A1 (en) 2018-09-28 2020-04-02 Acucela Inc. Inhibitors of vap-1
MX2021003559A (es) 2018-09-28 2021-08-24 Acucela Inc Inhibidores de vap-1.
CN112789277B (zh) 2018-10-22 2022-11-04 广东东阳光药业有限公司 胍类衍生物及其用途
EP3870162A4 (en) 2018-10-24 2022-08-24 Metacrine, Inc. SSAO INHIBITORS AND USES THEREOF
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
AU2020206477B2 (en) 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof

Similar Documents

Publication Publication Date Title
JP2021518377A5 (enExample)
JP2023513241A5 (enExample)
IL283539B1 (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
ES2642586T3 (es) Compuestos heterocíclicos condensados como moduladores de canales iónicos
WO2021161230A4 (en) Small molecule sting antagonists
JP2021518384A5 (enExample)
TWI825079B (zh) 新穎的芳基或雜芳基三唑酮衍生物或其鹽或包含彼等之醫藥組合物
JP2020527560A5 (enExample)
JP2022534303A5 (enExample)
JP2023521351A5 (enExample)
RU2008110949A (ru) Соединения и композиции-иммуносупрессанты
RU2010116352A (ru) Производные 1,1,1-трифтор-2-гидрокси-3-фенилпропана
RU2015139590A (ru) ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ
KR20140084146A (ko) 신규 옥사진 유도체 및 질환의 치료에서의 그의 용도
TWI803600B (zh) 新穎的三唑酮衍生物或其鹽及包含彼等之醫藥組合物
JP2024518556A5 (enExample)
EP2699557A1 (en) Aromatic amides and uses thereof
JP2016516805A5 (enExample)
JP2014523400A5 (enExample)
JP2022508218A5 (enExample)
JP2020503291A5 (enExample)
JP2025134819A (ja) 阻害剤化合物
JP2023528280A5 (enExample)
JP2024529088A5 (enExample)
KR20230146039A (ko) 신규한 화합물